Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

2013 San Antonio Breast Cancer Symposium (SABCS) /
Translational studies of CDK and PARP inhibitors

9th - 11th Dec 2013

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 19.12.13
Views: 3804
Rating:

Dr Geoffry Shapiro - Dana Farber Cancer Institute, Boston, USA

Dr Shapiro talks to ecancertv at SABCS 2013 about the inhibition of poly (ADP-ribose) polymerase (PARP).

PARP inhibition results in synthetic lethality in cells that have impaired HR, such as BRCA-deficient cells. In breast cancer, the primary activity of PARP inhibitor monotherapy has been in those cancers arising in BRCA carriers.

Inhibition of cell cycle kinases can be used to manipulate the activity of DNA repair pathways, creating exploitable cellular backgrounds that have increased sensitivity to DNA damaging agents.

The selectivity of rationally designed combinations for transformed cells will require careful preclinical assessment. Nonetheless, cell cycle and DNA repair pathways are expected to yield multiple new strategies for breast cancer.

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation